Clicky

Vir Biotechnology, Inc.(VIR)

Description: Vir Biotechnology, Inc., a clinical-stage immunology company, develops therapeutic products for the treatment and prevention of serious infectious diseases. It develops VIR-2218 and VIR-3434 for the treatment of hepatitis B virus; VIR-2482 for the prevention of influenza A virus; VIR-1111 for the prevention of human immunodeficiency virus, and VIR-2020 for the prevention of tuberculosis. The company has grant agreement with Bill & Melinda Gates Foundation and National Institutes of Health; option and license agreement with Brii Biosciences Limited and Brii Biosciences Offshore Limited; collaboration and license agreement Alnylam Pharmaceuticals, Inc.; collaboration, license and option agreement Visterra, Inc.; and license agreement with The Rockefeller University and MedImmune, Inc. It operates in the United States, Oregon, Massachusetts, and Switzerland. The company was founded in 2016 and is headquartered in San Francisco, California.


Keywords: Biotechnology Pharmaceutical Infectious Diseases Immunology Influenza Therapeutic Products Hepatitis B Coronavirus Tuberculosis Immunodeficiency Dimm Hepatitis B Virus Alnylam Pharmaceuticals Therapeutic Treatment Of Hepatitis Treatment Of Hepatitis B Medimmune Melinda Gates Foundation Rockefeller University Serious Infectious Diseases

Home Page: www.vir.bio

VIR Technical Analysis

499 Illinois Street
San Francisco, CA 94158
United States
Phone: 415 906 4324


Officers

Name Title
Dr. George A. Scangos Ph.D. Pres, CEO & Director
Mr. Howard Horn Exec. VP, CFO & Sec.
Dr. Ann M. Hanly Ph.D. Exec. VP & Chief Technology Officer
Dr. Phillip Pang M.D., Ph.D. Exec. VP, Chief Medical Officer & Interim Head of Research
Dr. Klaus Frueh Ph.D. Co-Founder & Scientific Advisor
Dr. Lawrence Corey M.D. Co-Founder & Scientific Advisor
Dr. Louis J. Picker M.D. Co-Founder & Scientific Advisor
Ms. Johanna Friedl-Naderer Exec. VP & COO
Mr. Steven J. Rice Exec. VP & Chief Admin. Officer
Ms. Heather Rowe Armstrong VP of Investor Relations

Exchange: NASDAQ

Country: US

Currency: US Dollar ($)

Forward PE: 4.3611
Trailing PE: 3.1311
Price-to-Book MRQ: 1.6037
Price-to-Sales TTM: 1.4094
IPO Date: 2019-10-11
Fiscal Year End: December
Full Time Employees: 444
Back to stocks